Targeting Immunometabolism in Glioblastoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jul 5

PMID 34222022

Citations 16

Authors

Aditya A Mohan

William H Tomaszewski

Aden P Haskell-Mendoza

Kelly M Hotchkiss

Kirit Singh

Jessica L Reedy

Peter E Fecci

John H Sampson

Mustafa Khasraw

Affiliations

Soon will be listed here.

Abstract

We have only recently begun to understand how cancer metabolism affects antitumor responses and immunotherapy outcomes. Certain immunometabolic targets have been actively pursued in other tumor types, however, glioblastoma research has been slow to exploit the therapeutic vulnerabilities of immunometabolism. In this review, we highlight the pathways that are most relevant to glioblastoma and focus on how these immunometabolic pathways influence tumor growth and immune suppression. We discuss hypoxia, glycolysis, tryptophan metabolism, arginine metabolism, 2-Hydroxyglutarate (2HG) metabolism, adenosine metabolism, and altered phospholipid metabolism, in order to provide an analysis and overview of the field of glioblastoma immunometabolism.

Citing Articles

Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L Bioeng Transl Med. 2025; 10(2):e10716.

PMID: 40060757 PMC: 11883117. DOI: 10.1002/btm2.10716.

Metabolic checkpoints in glioblastomas: targets for new therapies and non-invasive detection.

Li W, Wang Z, Chen S, Zuo M, Xiang Y, Yuan Y Front Oncol. 2024; 14:1462424.

PMID: 39678512 PMC: 11638224. DOI: 10.3389/fonc.2024.1462424.

Amino Acid Deprivation in Glioblastoma: The Role in Survival and the Tumour Microenvironment-A Narrative Review.

Du K, Grocott L, Anichini G, ONeill K, Syed N Biomedicines. 2024; 12(11).

PMID: 39595047 PMC: 11592029. DOI: 10.3390/biomedicines12112481.

Glioblastoma Therapy: Past, Present and Future.

Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).

PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.

Monitoring response to a clinically relevant IDH inhibitor in glioma-Hyperpolarized C magnetic resonance spectroscopy approaches.

Hong D, Kim Y, Mushti C, Minami N, Wu J, Cherukuri M Neurooncol Adv. 2023; 5(1):vdad143.

PMID: 38024238 PMC: 10681661. DOI: 10.1093/noajnl/vdad143.

References

Pastor-Anglada M, Perez-Torras S . Who Is Who in Adenosine Transport. Front Pharmacol. 2018; 9:627. PMC: 6010718. DOI: 10.3389/fphar.2018.00627. View

Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y . Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008; 62(2):493-503. DOI: 10.1227/01.neu.0000316018.51292.19. View

Allard D, Turcotte M, Stagg J . Targeting A2 adenosine receptors in cancer. Immunol Cell Biol. 2017; 95(4):333-339. DOI: 10.1038/icb.2017.8. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K . Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol. 2014; 35(6):5911-20. DOI: 10.1007/s13277-014-1784-5. View

Hayes A, Jayamanne D, Hsiao E, Schembri G, Bailey D, Roach P . Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018; 8(4):230-238. DOI: 10.1016/j.prro.2018.01.006. View

Intlekofer A, Dematteo R, Venneti S, Finley L, Lu C, Judkins A . Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab. 2015; 22(2):304-11. PMC: 4527873. DOI: 10.1016/j.cmet.2015.06.023. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Ma J, Benitez J, Li J, Miki S, Ponte de Albuquerque C, Galatro T . Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019; 35(3):504-518.e7. PMC: 6424615. DOI: 10.1016/j.ccell.2019.01.020. View

10.

Rzem R, Vincent M, Van Schaftingen E, Veiga-da-Cunha M . L-2-hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis. 2007; 30(5):681-9. DOI: 10.1007/s10545-007-0487-0. View

11.

Komohara Y, Ohnishi K, Kuratsu J, Takeya M . Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008; 216(1):15-24. DOI: 10.1002/path.2370. View

12.

Kim H, Kang J, Lee S, Choi W, Jeong L, Yang Y . A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells. Anticancer Res. 2010; 30(7):2823-30. View

13.

Paugh B, Bryan L, Paugh S, Wilczynska K, Alvarez S, Singh S . Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem. 2008; 284(6):3408-17. PMC: 2635028. DOI: 10.1074/jbc.M807170200. View

14.

Li L, Huang L, Ye H, Song S, Bajwa A, Lee S . Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest. 2012; 122(11):3931-42. PMC: 3484444. DOI: 10.1172/JCI63170. View

15.

Tea M, Poonnoose S, Pitson S . Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers (Basel). 2020; 12(1). PMC: 7017054. DOI: 10.3390/cancers12010111. View

16.

Garcia M, Carella A, Urdinguio R, Bayon G, Lopez V, Tejedor J . Epigenetic dysregulation of in human glioblastoma. Oncotarget. 2018; 9(40):25922-25934. PMC: 5995234. DOI: 10.18632/oncotarget.25406. View

17.

Mondal A, Smith C, DuHadaway J, Sutanto-Ward E, Prendergast G, Bravo-Nuevo A . IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine. 2016; 14:74-82. PMC: 5161421. DOI: 10.1016/j.ebiom.2016.11.013. View

18.

Bai A, Guo Y . Acid sphingomyelinase mediates human CD4 T-cell signaling: potential roles in T-cell responses and diseases. Cell Death Dis. 2017; 8(7):e2963. PMC: 5550889. DOI: 10.1038/cddis.2017.360. View

19.

Cairns R, Mak T . Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013; 3(7):730-41. DOI: 10.1158/2159-8290.CD-13-0083. View

20.

Kallies A, Zehn D, Utzschneider D . Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol. 2019; 20(2):128-136. DOI: 10.1038/s41577-019-0223-7. View